This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
AMAG Pharmaceuticals Inc
AMAG : NASDAQ : Health Care
$21.97 | %
Today's Range: 0.00 - 0.00
Avg. Daily Volume: 1,037,600
02/10/16 - 3:59 PM ET

Financial Analysis


AMAG PHARMACEUTICALS INC's gross profit margin for the third quarter of its fiscal year 2015 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. AMAG PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.05 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 367.03% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY15 Q3 FY14
Net Sales ($mil)96.1525.49
EBITDA ($mil)39.312.77
EBIT ($mil)22.342.5
Net Income ($mil)-20.581.46


Balance Sheet Q3 FY15 Q3 FY14
Cash & Equiv. ($mil)473.63386.24
Total Assets ($mil)2554.41451.39
Total Debt ($mil)1005.16165.78
Equity ($mil)919.96196.98


Profitability Q3 FY15 Q3 FY14
Gross Profit Margin79.4178.41
EBITDA Margin40.8810.87
Operating Margin23.239.79
Sales Turnover0.140.21
Return on Assets6.59-2.4
Return on Equity18.32-5.5
Debt Q3 FY15 Q3 FY14
Current Ratio2.4610.99
Debt/Capital0.520.46
Interest Expense14.223.13
Interest Coverage1.570.8


Share Data Q3 FY15 Q3 FY14
Shares outstanding (mil)34.722.03
Div / share0.00.0
EPS-0.620.06
Book value / share26.518.94
Institutional Own % n/a n/a
Avg Daily Volume1049157.01353039.0

Valuation


HOLD. AMAG PHARMACEUTICALS INC's P/E ratio indicates a significant discount compared to an average of 38.57 for the Biotechnology industry and a significant discount compared to the S&P 500 average of 21.13. For additional comparison, its price-to-book ratio of 0.91 indicates a significant discount versus the S&P 500 average of 2.51 and a significant discount versus the industry average of 10.43. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, AMAG PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
AMAG 4.58 Peers 38.57   AMAG 9.29 Peers 42.62

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

AMAG is trading at a significant discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

AMAG is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
AMAG 4.58 Peers 16.42   AMAG NM Peers 0.40

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

AMAG is trading at a significant discount to its peers.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

AMAG's negative PEG ratio makes this valuation measure meaningless.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
AMAG 0.91 Peers 10.43   AMAG 1131.37 Peers 39.78

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

AMAG is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

AMAG is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
AMAG 2.30 Peers 141.92   AMAG 290.76 Peers 53.93

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

AMAG is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

AMAG has a sales growth rate that significantly exceeds its peers.

 

 

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

Latest Stock Upgrades/Downgrades


Top Rated Stocks Top Rated Funds Top Rated ETFs